Biotechnology & Life Sciences Global On demand · 24-48h

Global Biomarker Driven Therapeutics Market Strategic Research Report

Global Biomarker Driven Therapeutics Market Strategic Resear…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Biomarker Driven Therapeutics Market
$78.4B2025
10.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Genomic Biomarker Therapeutics, Proteomic Biomarker Therapeutics, Oncology Applications

By Application: Autoimmune & Inflammatory, Neurology Applications, Cardiovascular Applications

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Market size 2025
$78.4B
Billion USD
Forecast CAGR
10.1%
2025-2032
Forecast 2032
$153.8B
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

The global biomarker driven therapeutics market represents one of the most consequential shifts in modern medicine, linking molecular intelligence directly to treatment selection. Valued at approximately USD 78.4 billion in 2024, the market encompasses the full spectrum of therapies—oncology, immunology, cardiovascular, and neurological—where patient eligibility, dosing, and response monitoring are governed by measurable biological indicators such as genetic mutations, protein expression levels, circulating tumor DNA, and receptor status. This tight coupling of companion diagnostics to therapeutic protocols has fundamentally altered drug development economics, allowing sponsors to design smaller, faster, and statistically more powerful trials by enrolling molecularly defined patient populations. As precision medicine transitions from an academic aspiration to standard clinical practice, biomarker driven therapeutics have attracted sustained capital from pharmaceutical conglomerates, specialty biotechs, and sovereign wealth funds alike.

Market snapshot

Global Biomarker Driven Therapeutics Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 10.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$78.4B
2025
Forecast
$153.8B
2032
CAGR
10.1%
2025–2032
Regiones
5
global
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Genomic Biomarker TherapeuticsProteomic Biomarker TherapeuticsOncology Applications
By Application
Autoimmune & InflammatoryNeurology ApplicationsCardiovascular Applications

Table of contents

Click a chapter to expand
01Executive Summary
  • 1.1 Market Synopsis
  • 1.2 Key Findings
  • 1.3 Strategic Recommendations
02Industry Overview & Forecast
  • 2.1 Market Definition & Scope
  • 2.2 Market Value Forecast, 2025-2032 (Value)
  • 2.3 CAGR Analysis & Confidence Intervals
  • 2.4 Historical Market Review, 2019-2024
  • 2.5 Scenario Analysis (Base, Bull, Bear Cases)
03Market Segmentation by Type
  • 3.1 Market by Type Overview
  • 3.2 Genomic & Genetic Biomarker-Based Therapeutics (Value)
  • 3.3 Proteomic Biomarker-Based Therapeutics (Value)
  • 3.4 Imaging Biomarker-Based Therapeutics (Value)
  • 3.5 Epigenomic Biomarker-Based Therapeutics (Value)
  • 3.6 Metabolomic Biomarker-Based Therapeutics (Value)
04Market Segmentation by Application
  • 4.1 Market by Application Overview
  • 4.2 Oncology (Solid Tumors & Hematological Malignancies) (Value)
  • 4.3 Autoimmune & Inflammatory Diseases (Value)
  • 4.4 Cardiovascular & Metabolic Diseases (Value)
  • 4.5 Neurological & Neurodegenerative Disorders (Value)
  • 4.6 Infectious Diseases & Virology (Value)
05Regional Market Forecast
  • 5.1 Regional Revenue Share & CAGR (2024 vs 2032)
  • 5.2 North America (Value)
  • 5.3 Europe (Value)
  • 5.4 Asia Pacific (Value)
  • 5.5 Middle East & Africa
  • 5.6 Latin America
06Country-Level Market Forecast
  • 6.1 Top Countries Overview
  • 6.2 United States
  • 6.3 Germany
  • 6.4 Japan
  • 6.5 China
  • 6.6 United Kingdom
  • 6.7 France
07Growth Drivers & Inhibitors
  • 7.1 Expansion of FDA Companion Diagnostic Co-Approval Pathways
  • 7.2 Rising Prevalence of Targetable Oncogenic Mutations (EGFR, ALK, KRAS, BRCA)
  • 7.3 Next-Generation Sequencing Cost Deflation Enabling Population-Scale Profiling
  • 7.4 Market Restraints & Challenges
  • 7.5 Opportunities & White-Space Analysis
08Key Company Profiles
  • 8.1 Roche Holding AG — Revenue, Strategy, Key Products
  • 8.2 AstraZeneca PLC — Revenue, Strategy, Key Products
  • 8.3 Pfizer Inc. — Revenue, Strategy, Key Products
  • 8.4 Novartis AG — Revenue, Strategy, Key Products
  • 8.5 Bristol-Myers Squibb Company — Revenue, Strategy, Key Products
  • 8.6 Merck & Co., Inc. (MSD) — Revenue, Strategy, Key Products
  • 8.7 Johnson & Johnson (Janssen Oncology) — Revenue, Strategy, Key Products
  • 8.8 Eli Lilly and Company — Revenue, Strategy, Key Products
  • 8.9 Guardant Health, Inc. — Revenue, Strategy, Key Products
  • 8.10 Foundation Medicine, Inc. (Roche subsidiary) — Revenue, Strategy, Key Products
09Competitive Landscape
  • 9.1 Market Concentration & Competitive Intensity
  • 9.2 Market Share Analysis (2024)
  • 9.3 Competitive Positioning Matrix
  • 9.4 Recent Developments: M&A, Partnerships & Product Launches (2023-2025)
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitute Products
  • 10.5 Competitive Rivalry Intensity
11PESTLE Analysis
  • 11.1 Political Factors
  • 11.2 Economic Factors
  • 11.3 Social & Demographic Factors
  • 11.4 Technological Factors
  • 11.5 Legal & Regulatory Factors
  • 11.6 Environmental Factors
12SWOT Analysis
  • 12.1 Market-Level Strengths
  • 12.2 Market-Level Weaknesses
  • 12.3 Strategic Opportunities
  • 12.4 External Threats
13Future Trends & Outlook
  • 13.1 Liquid Biopsy Integration as Real-Time Treatment Monitoring Biomarkers
  • 13.2 AI-Driven Multi-Omic Biomarker Discovery Shortening Target-to-IND Timelines
  • 13.3 Tumor-Agnostic Approval Frameworks Redefining Indication Boundaries
  • 13.4 Long-Term Market Outlook (2033-2035)
  • 13.5 Investment & M&A Activity Outlook

Frequently asked questions

What is the size of the biomarker driven therapeutics market?
The global biomarker driven therapeutics market was valued at approximately USD 78.4 billion in 2024 and is projected to reach USD 168.2 billion by 2032, reflecting the accelerating integration of companion diagnostics with targeted and immuno-oncology treatment regimens.
What is the CAGR of the biomarker driven therapeutics market?
The market is forecast to expand at a compound annual growth rate of approximately 10.1% over the period 2025 to 2032, driven by pipeline maturation in precision oncology, expanding reimbursement coverage for genomic profiling, and the commercialization of next-generation sequencing-linked therapeutic programs.
What is driving growth in the biomarker driven therapeutics market?
Three principal forces underpin market expansion. First, the FDA's co-approval pathway for companion diagnostics has reduced clinical trial failure rates by ensuring molecularly selected patient cohorts, increasing sponsor confidence in biomarker-stratified development programs. Second, the rapidly declining cost of next-generation sequencing—now below USD 200 per whole-genome sequence at scale—has made population-level profiling economically viable, widening the addressable patient pool for targeted therapies. Third, the growing prevalence of catalogued oncogenic mutations such as EGFR exon deletions, KRAS G12C, and BRCA1/2 loss-of-function variants has created well-defined patient segments that pharmaceutical companies can pursue with high regulatory and commercial predictability.
Who are the leading companies in the biomarker driven therapeutics market?
The market is led by Roche Holding AG, whose integrated diagnostics-therapeutics model through Foundation Medicine and Genentech provides unmatched biomarker pipeline depth. AstraZeneca holds a commanding position in EGFR- and HER2-driven oncology with Tagrisso and Enhertu. Merck & Co. dominates PD-L1 stratified immunotherapy through Keytruda, while Bristol-Myers Squibb competes directly with Opdivo across multiple biomarker-defined indications. Eli Lilly has rapidly ascended through KRAS G12C inhibition and targeted ADC programs.
Which region dominates the biomarker driven therapeutics market?
North America holds the largest regional share, accounting for approximately 43% of global revenue in 2024. This dominance reflects the United States' mature reimbursement infrastructure for companion diagnostic testing, the density of Phase II and III precision oncology trials conducted at NCI-designated cancer centers, and the FDA's receptiveness to biomarker-stratified accelerated approval applications. Europe ranks second, led by Germany, France, and the United Kingdom, where national genomic medicine programs have accelerated clinical adoption.
What segments are covered in this report?
The report segments the market by biomarker type—including genomic/genetic, proteomic, imaging-based, epigenomic, and metabolomic biomarker-driven therapies—and by therapeutic application area spanning oncology (solid tumors and hematological malignancies), autoimmune and inflammatory diseases, cardiovascular and metabolic diseases, neurological and neurodegenerative disorders, and infectious diseases. Regional coverage spans North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America, with country-level forecasts for the United States, Germany, Japan, China, the United Kingdom, and France.
What is the forecast period covered in this report?
This report covers the forecast period from 2025 to 2032, with 2024 serving as the base year. Historical trend analysis extends back to 2019 to capture pre- and post-pandemic shifts in clinical development prioritization and companion diagnostic adoption rates.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.